<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759133</url>
  </required_header>
  <id_info>
    <org_study_id>2015/18</org_study_id>
    <nct_id>NCT02759133</nct_id>
  </id_info>
  <brief_title>Preoperative Localization of Infraclinical Breast Tumors: Isotopic Localization by iodine125 Seed Versus Standard Localization Using a Metal Wire</brief_title>
  <acronym>IodineBreast</acronym>
  <official_title>Preoperative Localization of Infraclinical Breast Tumors: Isotopic Localization by iodine125 Seed Versus Standard Localization Using a Metal Wire: A Randomized Prospective Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Antoine Lacassagne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Antoine Lacassagne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a monocentric, non-inferiority, randomized cohort study with an open 1:1 ratio
      comparing the impact of iodine seed tumor localization (arm B) vs. standard localization
      using a metal guide (arm A) on the quality of the surgical resection margins in parallel
      groups with an interim analysis in patients with breast cancer.

      Randomization will be performed using histologic status stratification: in situ ductal
      /invasive lobular +/- an in situ component / invasive ductal +/- an in situ component.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The widespread development of organized breast cancer screening has enabled diagnosis of
      nonpalpable, small-size cancer lesions (infraclinical stage). When conservative breast
      surgery is scheduled (tumorectomy or zonectomy), preoperative localization of the lesion is
      mandatory. To date, wire localization of non-palpable lesions is the most frequently used
      technique worldwide.

      Nevertheless, this technique presents a number of drawbacks:

        -  it is very uncomfortable for the patient. The wire is implanted transcutaneously,
           crosses the skin to reach the lesion and then protrudes outside the breast, thus
           limiting the patient's mobility and giving rise to discomfort and even pain during
           movement.

        -  furthermore, and for the same above-mention reasons, there is a risk of the wire
           becoming dislodged, breaking or being disinserted during patient movements (transfer
           between units, pre-op shower, installation in the operating room), thus jeopardizing the
           quality of the planned surgery by increasing the risk of unhealthy resection margins or
           even of non-removal of the tumor. Cases have even been reported of intrapulmonary wire
           migration.

        -  in order to lessen these risks, the wire must be placed as late as possible before
           transfer to the surgical wing (the previous day at the earliest). Consequently,
           organizing the patient's transfer, particularly in the event of outpatient surgery (less
           than 12h at the hospital) becomes complicated and requires coordination between the
           different units in charge of preoperative management (radiology, nuclear medicine,
           admittance, and operating room) and early inclusion of these patients in the operating
           room schedule or postponement of surgery in the event of migration or displacement of
           the wire. These various constraints can result in a reduction of the number of patients
           able to benefit from outpatient management, as demonstrated by Dravet et al. Several
           alternative techniques have been put forward in order to overcome these difficulties,
           including radioguided seed localization (RSL), which consists in implanting a sealed
           source of radioactive iodine125 (iodine seed) inside the tumor to provide a preoperative
           marker which can be monitored by the surgeon using a gamma probe. The RSL technique is
           currently used in Europe (Netherlands), Canada and the USA.

      This technique appears to offer several advantages:

        -  It is a simple radiologic technique performed under ultrasound or stereotaxic control,
           allowing accurate localization of the lesion with no risk of the marker moving or being
           displaced,

        -  It requires no special training for surgeons already skilled in the use of gamma probes
           in the sentinel node technique,

        -  It allows concomitant, interference-free performance of sentinel node surgery by means
           of a gamma probe able to detect specifically Tc99m and/or Iodine 125,

        -  It is free of organizational localization constraints limiting access to outpatient
           surgery, which ranks as a high priority for our governing bodies (50% of all surgeries
           will be performed on an outpatient basis by 2016). As the half-life of iodine seeds is
           60 days, it should be possible, in theory, to insert them several days, or even several
           months, before surgery. In this way, patient transfer is simplified and the turnover of
           the operating block for outpatient management can be increased. Moreover, this
           localization method could also be used for tumorectomies following neoadjuvant
           chemotherapy,

        -  It presents none of the drawbacks related to patient mobility. Patient comfort is
           enhanced and the patient is able to move freely, with fewer risks of displacement or
           disinsertion, and less pain, etc.

        -  Patient satisfaction is higher among those women who have undergone iodine seed
           localization as opposed to the conventional localization techniques

      Furthermore, various studies have demonstrated the safety of this technique in terms of
      radiation protection as radiation is minimal to the patient (equivalent to the amount
      received from two mammography views) as well as to the staff. Its reliability regarding the
      surgical excision procedure (positive or inadequate margin rates, revision surgery rates) has
      been demonstrated in 3 randomized studies with a high level of evidence.

      Thus, in 2001, Gray et al. published the first randomized study comparing the RSL technique
      with the conventional wire method and showed the superiority of iodine seed localization in
      terms of positive margin and surgical revision rates (RSL 26% vs WL 26%, p=0.02) with no
      concomitant increase in tumorectomy specimen volumes or marker migration rates. More
      recently, Lovrics et al. (2011) and Bloomquist et al (2015) published randomized
      non-inferiority studies highlighting the equivalent results between these two techniques
      regarding the quality of tumor excision (positive margins rates in: RSL 15.1% vs WL 19%
      p=0.389, and in: RSL 19.4% vs 15.3%, p=0.53). In addition, the RSL method showed a
      significant advantage regarding operating times and pain experienced by patients during the
      localization procedure.

      No French team has investigated this localization method on account of legal constraints.
      Nonetheless, it would appear that the wire localization technique does not satisfy surgical
      teams since another pre-operative localization technique involving injection of Tc99m into
      contact with the tumor has been developed over the past few years to replace the wire method.
      This procedure has met with little success, and has been gradually abandoned. Unfortunately,
      injecting Tc99m around the tumor renders the surgical procedure less precise or necessitates
      resecting a large segment of the gland with potentially damaging esthetic repercussions.
      Implantation of a sealed radioactive source such as an iodine seed helps mitigate this
      drawback.

      This study project aims to evaluate the feasibility and safety of using 1 grain of iodine for
      localization purposes by means of a randomized comparative study comparing wire localization
      with iodine seed localization in patients presenting an in situ, biopsy-proven, non-palpable
      invasive or ductal breast carcinoma requiring conservative surgical management associated, or
      not, with an axillary procedure (SN removal or axillary curettage).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>comparison of the rates of incomplete resection of the tumorectomy specimen defined according to the recommendations of the American Society of Breast Surgeons</measure>
    <time_frame>up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>surgical revision rate</measure>
    <time_frame>up to 24 months</time_frame>
    <description>Surgical revision rates are assessed by the number of surgical procedures performed for insufficient margins using the two techniques bearing in mind the analysis of systematic recuts and the surgical potential for performing revisions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analog Score for pain</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of surgical procedures</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The duration of the localization procedure (in minutes) will be calculated from the moment the patient enters the radiology room for localization until the date of entry into the operating room. If this duration were to be extensive (several days), different groupings will be calculated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>A - A standard Localization technique</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A standard Localization technique : Metal wire as localization technique for breast cancer surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Experimental Localization technique</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental Localization technique: Radioactive Iodine seed as localization technique for breast cancer surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Metal wire</intervention_name>
    <description>Localization technique for breast surgery using metal wire</description>
    <arm_group_label>A - A standard Localization technique</arm_group_label>
    <other_name>standard Localization technique</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radioactive Iodine Seed</intervention_name>
    <description>Localization technique for breast surgery using Radioactive Iodine Seed</description>
    <arm_group_label>B - Experimental Localization technique</arm_group_label>
    <other_name>Experimental Localization technique</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18 or over

          -  Patients suffering from unifocal or in situ invasive or ductal breast cancer proven by
             anatomopathologic analysis (biopsy).

          -  Non-palpable tumor measuring at least 5 mm (minimum size deemed sufficient for the
             lesion to be visible by ultrasound) and â‰¤ 30 mm, visible by ultrasound and
             constituting a mass.

          -  Patients needing conservative first surgery management by preoperative tumor
             localization. For women of childbearing age, an effective contraceptive is mandatory
             throughout the study and up to 6 months post-operatively.

          -  Patients who have been made aware of the information sheet and have given their
             written signed informed consent.

          -  Patients benefitting from social health insurance coverage.

        Exclusion Criteria:

          -  Patients with a history of homolateral breast cancer.

          -  Patients who have undergone neoadjuvant chemotherapy.

          -  Multifocal or multicentric cancer.

          -  Metastatic breast cancer.

          -  Cancer presenting in the form of microcalcifications with no visible mass.

          -  Vulnerable patients: pregnant or breastfeeding women, women deprived of their freedom
             by administrative or judicial decree, adults subject to a legal protection order or
             unable to give their consent.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel BARRANGER, phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Antoine Lacassagne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine LOVERA</last_name>
    <email>christine.lovera@nice.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maeva MAURIN</last_name>
    <email>maeva.maurin@nice.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Antoine LACASSAGNE</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charline GILLARD, md</last_name>
      <email>charline.gillard@nice.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Emmanuel BARRANGER, phd</last_name>
      <email>emmanuel.barranger@nice.unicancer.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.centreantoinelacassagne.org/</url>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>May 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

